Xylem EPS (Diluted) decreased by 42.3% to $0.79 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.5%, from $0.69 to $0.79. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 13.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.62 | $0.63 | $0.62 | $0.45 | $0.62 | $0.07 | $0.82 | $0.54 | $0.45 | $0.63 | $1.17 | $0.63 | $0.80 | $0.89 | $1.33 | $0.69 | $0.93 | $0.93 | $1.37 | $0.79 |
| QoQ Change | — | +1.6% | -1.6% | -27.4% | +37.8% | -88.7% | >999% | -34.1% | -16.7% | +40.0% | +85.7% | -46.2% | +27.0% | +11.2% | +49.4% | -48.1% | +34.8% | +0.0% | +47.3% | -42.3% |
| YoY Change | — | — | — | — | +0.0% | -88.9% | +32.3% | +20.0% | -27.4% | +800.0% | +42.7% | +16.7% | +77.8% | +41.3% | +13.7% | +9.5% | +16.3% | +4.5% | +3.0% | +14.5% |